Gastrointestinal Hormones As Potential Adjuvant Treatment of Exocrine Pancreatic Adenocarcinoma

Overview

Journal Int J Pancreatol

Specialty Gastroenterology

Date 1999 Jan 5

PMID 9873951

Citations 3

Authors

W E Fisher

P Muscarella

L G Boros

W J Schirmer

Affiliations

Soon will be listed here.

Abstract

Conclusion: Gastrointestinal hormones and their antagonists can alter the growth of pancreatic adenocarcinoma in vitro and in vivo. The potential clinical benefit of this approach deserves further study.

Background: Epithelial cell growth is normally under hormonal control. Hormones also affect the growth of many epithelial cancers, and this fact is used to modify tumor growth. Pancreatic epithelial cell growth is under the influence of gastrointestinal hormones. This article reviews experiments designed to determine the effect of gastrointestinal hormones on the growth of pancreatic adenocarcinoma.

Methods: Eighty-eight articles were identified from a Medline search using the terms pancreatic adenocarcinoma and the individual names of gastrointestinal hormones. The experimental design and results of these studies are reviewed.

Results: In general, somatostatin, vasoactive intestinal polypeptide, pancreatic polypeptide, and pancreastatin inhibit pancreatic adenocarcinoma growth. Cholecystokinin, secretin, bombesin, gastrin, EGF, TGF-alpha, insulin, and IGF-1 have a growth-promoting effect.

Citing Articles

Defining the cancer master switch.

Balentine C, Berger D, Liu S, Chen C, Nemunaitis J, Brunicardi F World J Surg. 2011; 35(8):1738-45.

PMID: 21286716 DOI: 10.1007/s00268-010-0941-2.

Pancreatic cancer - a continuing challenge in oncology.

Zalatnai A Pathol Oncol Res. 2003; 9(4):252-63.

PMID: 14688834 DOI: 10.1007/BF02893388.

Gut peptide receptor expression in human pancreatic cancers.

Ehlers R, Kim S, Zhang Y, Ethridge R, Murrilo C, Hellmich M Ann Surg. 2000; 231(6):838-48.

PMID: 10816627 PMC: 1421073. DOI: 10.1097/00000658-200006000-00008.

References

HUBAY C, Arafah B, Gordon N, Guyton S, Crowe J . Hormone receptors. An update and application. Surg Clin North Am. 1984; 64(6):1155-72. DOI: 10.1016/s0039-6109(16)43487-0. View

Abbruzzese J, Gholson C, Daugherty K, Larson E, Dubrow R, Berlin R . A pilot clinical trial of the cholecystokinin receptor antagonist MK-329 in patients with advanced pancreatic cancer. Pancreas. 1992; 7(2):165-71. DOI: 10.1097/00006676-199203000-00006. View

Smith J, Derynck R, Korc M . Production of transforming growth factor alpha in human pancreatic cancer cells: evidence for a superagonist autocrine cycle. Proc Natl Acad Sci U S A. 1987; 84(21):7567-70. PMC: 299340. DOI: 10.1073/pnas.84.21.7567. View

Steffensrud S, Erichsen H, Roysland P, Halvorsen T, Klepp R, Klepp O . Treatment with secretin and a cholecystokinin-like peptide in patients with pancreatic cancer. A pilot study. Scand J Gastroenterol. 1984; 19(7):909-15. View

Huguier M, Samama G, Testart J, Mauban S, Fingerhut A, Nassar J . Treatment of adenocarcinoma of the pancreas with somatostatin and gonadoliberin (luteinizing hormone-releasing hormone). The French Associations for Surgical Research. Am J Surg. 1992; 164(4):348-53. DOI: 10.1016/s0002-9610(05)80903-1. View

Hudd C, LaRegina M, Devine J, Palmer D, Herbold D, Beinfeld M . Response to exogenous cholecystokinin of six human gastrointestinal cancers xenografted in nude mice. Am J Surg. 1989; 157(4):386-94. DOI: 10.1016/0002-9610(89)90582-5. View

Smith J, Rickabaugh C, McLaughlin P, Zagon I . Cholecystokinin receptors and PANC-1 human pancreatic cancer cells. Am J Physiol. 1993; 265(1 Pt 1):G149-55. DOI: 10.1152/ajpgi.1993.265.1.G149. View

Tatemoto K, Efendic S, Mutt V, Makk G, Feistner G, Barchas J . Pancreastatin, a novel pancreatic peptide that inhibits insulin secretion. Nature. 1986; 324(6096):476-8. DOI: 10.1038/324476a0. View

Szepeshazi K, Schally A, Cai R, Radulovic S, Milovanovic S, Szoke B . Inhibitory effect of bombesin/gastrin-releasing peptide antagonist RC-3095 and high dose of somatostatin analogue RC-160 on nitrosamine-induced pancreatic cancers in hamsters. Cancer Res. 1991; 51(21):5980-6. View

10.

Appel M, Meijers M, Lamers C, Rovati L, Jansen J, Woutersen R . Role of cholecystokinin in dietary fat-promoted azaserine-induced pancreatic carcinogenesis in rats. Br J Cancer. 1992; 66(1):46-50. PMC: 1977907. DOI: 10.1038/bjc.1992.214. View

11.

Hajri A, Balboni G, Koenig M, Garaud J, Damge C . Gastrin-releasing peptide: in vivo and in vitro growth effects on an acinar pancreatic carcinoma. Cancer Res. 1992; 52(13):3726-32. View

12.

Andren-Sandberg A, Dawiskiba S, Ihse I . Studies of the effect of cerulein administration on experimental pancreatic carcinogenesis. Scand J Gastroenterol. 1984; 19(1):122-8. View

13.

Fisher W, Boros L, Schirmer W . Insulin promotes pancreatic cancer: evidence for endocrine influence on exocrine pancreatic tumors. J Surg Res. 1996; 63(1):310-3. DOI: 10.1006/jsre.1996.0266. View

14.

Bell Jr R, Kuhlmann E, Jensen R, Longnecker D . Overexpression of cholecystokinin receptors in azaserine-induced neoplasms of the rat pancreas. Cancer Res. 1992; 52(12):3295-9. View

15.

Korc M, Matrisian L, Planck S, Magun B . Binding of epidermal growth factor in rat pancreatic acini. Biochem Biophys Res Commun. 1983; 111(3):1066-73. DOI: 10.1016/0006-291x(83)91408-0. View

16.

Fisher W, Muscarella P, ODorisio T, ODorisio M, Kim J, Doran T . Expression of the somatostatin receptor subtype-2 gene predicts response of human pancreatic cancer to octreotide. Surgery. 1996; 120(2):234-40; discussion 240-1. DOI: 10.1016/s0039-6060(96)80293-5. View

17.

Johnson F, LaRegina M, Martin S, Bashiti H . Cholecystokinin inhibits pancreatic and hepatic carcinogenesis. Cancer Detect Prev. 1983; 6(3):389-402. View

18.

Canobbio L, Boccardo F, Cannata D, Gallotti P, Epis R . Treatment of advanced pancreatic carcinoma with the somatostatin analogue BIM 23014. Preliminary results of a pilot study. Cancer. 1992; 69(3):648-50. DOI: 10.1002/1097-0142(19920201)69:3<648::aid-cncr2820690308>3.0.co;2-j. View

19.

Smith J, Kramer S, Solomon T . CCK stimulates growth of six human pancreatic cancer cell lines in serum-free medium. Regul Pept. 1991; 32(3):341-9. DOI: 10.1016/0167-0115(91)90027-e. View

20.

Alexander R, Upp Jr J, Poston G, Townsend Jr C, Singh P, Thompson J . Bombesin inhibits growth of human pancreatic adenocarcinoma in nude mice. Pancreas. 1988; 3(3):297-302. DOI: 10.1097/00006676-198805000-00010. View